Clinical data | |
---|---|
Trade names | Canespor, many others |
AHFS/ Drugs.com | International Drug Names |
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.056.651 |
Chemical and physical data | |
Formula | C22H18N2 |
Molar mass | 310.400 g·mol−1 |
3D model ( JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Bifonazole (trade name Canespor among others [1]) is an imidazole antifungal drug used in form of ointments.
It was patented in 1974 and approved for medical use in 1983. [2] There are also combinations with carbamide for the treatment of onychomycosis.
The most common side effect is a burning sensation at the application site. Other reactions, such as itching, eczema or skin dryness, are rare. [3] Bifonazole is a potent aromatase inhibitor in vitro. [4] [5]
Bifonazole has a dual mode of action. It inhibits fungal ergosterol biosynthesis at two points, via transformation of 24-methylendihydrolanosterol to desmethylsterol, together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs. [3] [6]
Six hours after application, bifonazole concentrations range from 1000 μg/ cm3 in the stratum corneum to 5 μg/cm3 in the papillary dermis. [3]